Last reviewed · How we verify
Triiodomethane (IODOFORM)
Iodoform, a marketed antiseptic agent, holds a niche position in the pharmaceutical market with a key composition patent expiring in 2028. Its primary competitive advantage lies in its long-standing use and established safety profile, distinguishing it from off-patent alternatives like nitrofurazone and other same-class competitors. The primary risk to Iodoform's market position is the availability of multiple generic options, such as nitrofurazone, which could erode its market share.
At a glance
| Generic name | IODOFORM |
|---|---|
| Drug class | iodoform |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Biodentine Pulpotomy vs Metapex Pulpectomy in Primary Molars: Clinical & Radiographic Comparison of Outcomes in Irreversible Pulpitis Cases (NA)
- Evaluation of Zinc Oxide Eugenol and Iodoform-Calcium Hydroxide as Filling Materials in Primary Molar Root Canals Prepared by Rotary and Manual Files (NA)
- Antibacterial Activity of Calcium Hydroxide and Betamethasone in Apical Periodontitis
- Lesion Sterilization Tissue Repair and Conventional Pulpectomy in Primary Molars (NA)
- Zinc Oxide-Ozonated Olive Oil vs Metapex in Primary Anterior Teeth (NA)
- Pulpotomy With CEM vs Pulpectomy With Ca(OH)2/Iodoform in Primary Molars (NA)
- Evaluation of Pulpotomy Versus Pulpectomy in Primary Molars With Irreversible Pulpitis or Necrotic Pulp (NA)
- Comparison of LSTR and Pulpectomy in Primary Molars of Pediatric Patients (LSTR-PULP) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triiodomethane CI brief — competitive landscape report
- Triiodomethane updates RSS · CI watch RSS